Jaelim Cho1, Stephen J Pandol2, Maxim S Petrov3. 1. School of Medicine, University of Auckland, Auckland, New Zealand. 2. Division of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 3. School of Medicine, University of Auckland, Auckland, New Zealand. max.petrov@gmail.com.
Abstract
AIMS: The aim was to investigate sex- and age-stratified risks of cause-specific death and life expectancy in individuals with post-pancreatitis diabetes mellitus (PPDM). METHODS: Nationwide data on mortality in New Zealand were obtained. For two head-to-head comparisons (PPDM versus type 2 diabetes mellitus [T2DM]; PPDM versus type 1 diabetes mellitus [T1DM]), the groups were matched on age, sex, and calendar year of diabetes diagnosis. Multivariable Cox regression analyses were conducted to estimate risks of vascular, cancer, and non-vascular non-cancer mortality. Remaining life expectancy at age of diabetes diagnosis was estimated using the Chiang II method. RESULTS: A total of 15,848 individuals (1,132 PPDM, 3,396 T1DM, and 11,320 T2DM) were included. The risks of vascular mortality and non-vascular non-cancer mortality did not differ significantly between PPDM and T2DM or T1DM. PPDM was associated with a significantly higher risk of cancer mortality compared with T2DM (adjusted hazard ratio, 1.32; 95% confidence interval, 1.08-1.63) or T1DM (adjusted hazard ratio, 1.65; 95% confidence interval, 1.27-2.13). The risk of cancer mortality associated with PPDM (versus T2DM) was significantly higher in women than in men (p for interaction = 0.003). This sex difference in cancer mortality risk was also significant in the comparison between PPDM and T1DM (p for interaction = 0.006). Adults of both sexes with PPDM had the lowest remaining life expectancy (in comparison with T2DM or T1DM) up to 64 years of age. CONCLUSIONS: People with PPDM have a higher risk of cancer mortality compared with those with T2DM or T1DM. This is especially pronounced in women. Young and middle-aged adults with PPDM have a lower life expectancy compared with their counterparts with T2DM or T1DM.
AIMS: The aim was to investigate sex- and age-stratified risks of cause-specific death and life expectancy in individuals with post-pancreatitis diabetes mellitus (PPDM). METHODS: Nationwide data on mortality in New Zealand were obtained. For two head-to-head comparisons (PPDM versus type 2 diabetes mellitus [T2DM]; PPDM versus type 1 diabetes mellitus [T1DM]), the groups were matched on age, sex, and calendar year of diabetes diagnosis. Multivariable Cox regression analyses were conducted to estimate risks of vascular, cancer, and non-vascular non-cancer mortality. Remaining life expectancy at age of diabetes diagnosis was estimated using the Chiang II method. RESULTS: A total of 15,848 individuals (1,132 PPDM, 3,396 T1DM, and 11,320 T2DM) were included. The risks of vascular mortality and non-vascular non-cancer mortality did not differ significantly between PPDM and T2DM or T1DM. PPDM was associated with a significantly higher risk of cancer mortality compared with T2DM (adjusted hazard ratio, 1.32; 95% confidence interval, 1.08-1.63) or T1DM (adjusted hazard ratio, 1.65; 95% confidence interval, 1.27-2.13). The risk of cancer mortality associated with PPDM (versus T2DM) was significantly higher in women than in men (p for interaction = 0.003). This sex difference in cancer mortality risk was also significant in the comparison between PPDM and T1DM (p for interaction = 0.006). Adults of both sexes with PPDM had the lowest remaining life expectancy (in comparison with T2DM or T1DM) up to 64 years of age. CONCLUSIONS: People with PPDM have a higher risk of cancer mortality compared with those with T2DM or T1DM. This is especially pronounced in women. Young and middle-aged adults with PPDM have a lower life expectancy compared with their counterparts with T2DM or T1DM.
Authors: Jennifer S Lin; Margaret A Piper; Leslie A Perdue; Carolyn M Rutter; Elizabeth M Webber; Elizabeth O'Connor; Ning Smith; Evelyn P Whitlock Journal: JAMA Date: 2016-06-21 Impact factor: 56.272
Authors: Michael Davidson; Anna Dorothea Wagner; Kyriakos Kouvelakis; Henry Nanji; Naureen Starling; Ian Chau; David Watkins; Sheela Rao; Clare Peckitt; David Cunningham Journal: Eur J Cancer Date: 2019-09-19 Impact factor: 9.162
Authors: Linda L Humphrey; Mark Deffebach; Miranda Pappas; Christina Baumann; Kathryn Artis; Jennifer Priest Mitchell; Bernadette Zakher; Rongwei Fu; Christopher G Slatore Journal: Ann Intern Med Date: 2013-09-17 Impact factor: 25.391
Authors: Christine L Parr; G David Batty; Tai Hing Lam; Federica Barzi; Xianghua Fang; Suzanne C Ho; Sun Ha Jee; Alireza Ansary-Moghaddam; Konrad Jamrozik; Hirotsugu Ueshima; Mark Woodward; Rachel R Huxley Journal: Lancet Oncol Date: 2010-06-30 Impact factor: 41.316
Authors: Emanuele Di Angelantonio; Shilpa Bhupathiraju; David Wormser; Pei Gao; Stephen Kaptoge; Amy Berrington de Gonzalez; Benjamin Cairns; Rachel Huxley; Chandra Jackson; Grace Joshy; Sarah Lewington; JoAnn Manson; Neil Murphy; Alpa Patel; Jonathan Samet; Mark Woodward; Wei Zheng; Maigen Zhou; Narinder Bansal; Aurelio Barricarte; Brian Carter; James Cerhan; George Smith; Xianghua Fang; Oscar Franco; Jane Green; Jim Halsey; Janet Hildebrand; Keum Jung; Rosemary Korda; Dale McLerran; Steven Moore; Linda O'Keeffe; Ellie Paige; Anna Ramond; Gillian Reeves; Betsy Rolland; Carlotta Sacerdote; Naveed Sattar; Eleni Sofianopoulou; June Stevens; Michael Thun; Hirotsugu Ueshima; Ling Yang; Young Yun; Peter Willeit; Emily Banks; Valerie Beral; Zhengming Chen; Susan Gapstur; Marc Gunter; Patricia Hartge; Sun Jee; Tai-Hing Lam; Richard Peto; John Potter; Walter Willett; Simon Thompson; John Danesh; Frank Hu Journal: Lancet Date: 2016-07-13 Impact factor: 79.321